Calcitonin Gene Related Peptide - Pipeline Review, H1 2020

March 2020 | 81 pages | ID: CF0739DDC77BEN
Global Markets Direct

Abstracts

Calcitonin Gene Related Peptide - Pipeline Review, H1 2020

SUMMARY

Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 10 molecules. The latest report Calcitonin Gene Related Peptide - Pipeline Review, H1 2020, outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 2, 1, 5 and 2 respectively. Report covers products from therapy areas Central Nervous System and Immunology which include indications Migraine, Cluster Headache Syndrome (Cluster Headache), Dental Pain (Toothache/Tooth Pain), Fibromyalgia (Fibromyalgia Syndrome), Inflammatory Pain, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Osteoarthritis Pain, Pain, Psoriasis and Traumatic Pain.

Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
• The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
• The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide (CGRP) - Overview
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
AfaSci Inc
Aptarion biotech AG
Eli Lilly and Co
H. Lundbeck AS
Living Cell Technologies Ltd
Nepsone ehf
Pharmnovo AB
Serometrix LLC
Teva Pharmaceutical Industries Ltd
United Neuroscience Ltd
Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
AFAP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eptinezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide (CGRP) - Dormant Products
Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AfaSci Inc, H1 2020
Pipeline by Aptarion biotech AG, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by H. Lundbeck AS, H1 2020
Pipeline by Living Cell Technologies Ltd, H1 2020
Pipeline by Nepsone ehf, H1 2020
Pipeline by Pharmnovo AB, H1 2020
Pipeline by Serometrix LLC, H1 2020
Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020
Pipeline by United Neuroscience Ltd, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

AfaSci Inc
Aptarion biotech AG
Eli Lilly and Co
H. Lundbeck AS
Living Cell Technologies Ltd
Nepsone ehf
Pharmnovo AB
Serometrix LLC
Teva Pharmaceutical Industries Ltd
United Neuroscience Ltd